Intranasal Ketorolac

  title={Intranasal Ketorolac},
  author={Karly P Garnock-jones},
  journal={Clinical Drug Investigation},
Ketorolac is a member of the pyrrolo-pyrrole group of NSAIDs, and has been available in several formulations for some time, for the treatment of pain. Intranasal ketorolac has recently become available.Intranasal ketorolac was effective in providing short-term relief from postoperative pain in four well designed, phase II or III trials.In the two phase III trials, a single intranasal dose of ketorolac 31.5 mg, with or without backup analgesia, was associated with significantly higher 6-hour… 
6 Citations
Ketorolac Tromethamine Spray Prevents Postendotracheal-Intubation-Induced Sore Throat after General Anesthesia
It is demonstrated that preanesthesia 5% ketorolac tromethamine spray could effectively decrease postendotracheal-intubation-induced sore throat in patients undergoing general anesthesia.
Pharmacokinetics and pharmacodynamics of new acute treatments for migraine
Although available data do not conclusively indicate the superiority of a class over the others, the pharmacodynamics explains the peculiar tolerability and safety profile of different drug classes emerging from clinical trials.
Narrative review shows that the short‐term use of ketorolac is safe and effective in the management of moderate‐to‐severe pain in children
It is found that gastrointestinal side effects were mainly reported with prolonged use, significant bleeding was reported in adenotonsillectomy, and adverse renal effects appeared to be limited to patients with specific coexisting risk factors.
The Routes of Administration for Acute Postoperative Pain Medication
A comprehensive analysis was performed on the different routes of administration of acute postoperative pain medications and their indications and limitations, focusing on recent evidence and international recommendations.
Sonochemical Formation of Copper/Iron-Modified Graphene Oxide Nanocomposites for Ketorolac Delivery.
A feasible sonochemical approach is described for the preparation of copper/iron-modified graphene oxide nanocomposites through ultrasonication (20 kHz, 18 W cm-2 ) of an aqueous solution containing


Ketorolac. A reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management.
Ketorolac is a strong analgesic with a tolerability profile which resembles that of other NSAIDs when used in accordance with current dosage guidelines, this drug provides a useful alternative, or adjuvant, to opioids in patients with moderate to severe pain.
Intranasal ketorolac for acute postoperative pain
Intranasal ketorolac was well tolerated and provided effective pain relief within 20 minutes with reduced opioid analgesia use and may have more relevance for use in outpatient settings and ambulatory surgery or fast-track surgical procedures.
The Safety and Analgesic Efficacy of Intranasal Ketorolac in Patients with Postoperative Pain
Thirty milligrams of intranasal ketorolac demonstrated significant analgesic efficacy compared to 10 mg of intrastate ketorlac and placebo in patients undergoing major surgery.
Intranasal ketorolac for postoperative pain: a phase 3, double-blind, randomized study.
In ketorolac was well tolerated and effective in treating moderate-to-severe postoperative pain in inpatients; the convenience of IN dosing suggests that its usefulness in the ambulatory care setting should be evaluated.
Pharmacokinetics and Safety of Ketorolac Following Single Intranasal and Intramuscular Administration in Healthy Volunteers
In ketorolac offers a therapeutic alternative to IM administration and may provide benefits in the clinical setting and dose proportionality was noted between the 15‐ and 30‐mg IN and IM dose levels.
Intranasal ketorolac for pain secondary to third molar impaction surgery: a randomized, double-blind, placebo-controlled trial.
  • G. Grant, D. Mehlisch
  • Medicine
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • 2010
Ketorolac 0.45% Ophthalmic Solution
In two identically designed, randomized, double-masked, multicentre trials in adult patients undergoing cataract extraction, the proportions of patients with a summed ocular inflammation score of zero for anterior chamber cell count plus anterior chamber flare on day 14 after surgery were significantly greater in those treated with topical ketorolac 0.45% ophthalmic solution.
Single dose oral analgesics for acute postoperative pain in adults.
Data from all Cochrane Reviews that have assessed the effects of pharmaceutical interventions for acute pain in adults with at least moderate pain following surgery, who have been given a single dose of oral analgesic taken alone are summarized.
SPRIX (ketorolac tromethamine nasal spray) US prescribing information [online]. Available from URL: 022382s000lbl.pdf [Accessed
  • 2012